glp-1 summit 2025 GLP1-S - Semaglutide - Summit

Description

They also face an increased risk of serious and potentially life-threatening health problems

Patients should engage in regular follow-ups with their healthcare provider to assess the effectiveness of the treatment and make necessary adjustments, ensuring that the benefits outweigh any potential risks over time

Reduced/Restricted Practice States: In states like Texas , Florida , Pennsylvania , and California (until 2026), you must have a collaborative agreement or supervising physician to prescribe

3 In a 500-patient study, postoperative infection with HSV-1 was seen in 7.4 percent of patients postablative laser procedure, regardless of prior history

A 2024 retrospective chart review found that 67% of IBS-D (diarrhea-predominant) patients using GLP-1 medications reported moderate to significant symptom improvement within 812 weeks of starting treatment